Carol Fabian recalls the emotional hardship that came with treating women for breast cancer in the 1970s and eighties.
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is more than halfway to its recruiting goal of 128,905 participants, with more than 20% of participants in the United States being Black. Recruitment of women from diverse backgrounds is vital to ensuring that TMIST trial results will be applicable across races, ethnicities, and under-served communities.
A study led by researchers from MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
The American Cancer Society will launch two national roundtables—one focused on cervical cancer, the other breast cancer—to bring together leading organizations and experts with the goal of improving health equity and access to cancer screening.
Research from Sanford Burnham Prebys has revealed significant molecular differences between the breast cells of white and Black women that help explain why Black women experience higher breast cancer mortality.
Mateusz Opyrchal was named the inaugural Vera Bradley Foundation Scholar in Breast Cancer Discovery in the Vera Bradley Foundation Center for Breast Cancer Research at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
Researchers at Yale Cancer Center showed that inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing.
Veru Inc. and Eli Lilly and Company entered into a clinical trial collaboration and supply agreement to evaluate the efficacy and safety of enobosarm, Veru’s first-in-class, selective androgen receptor targeting agonist, in combination with Lilly’s Verzenio (abemaciclib), a CDK4/6 inhibitor, as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer.
An anonymous donor has made a $25 million gift to UNC Lineberger Comprehensive Cancer Center to establish the UNC Lineberger Center for Triple Negative Breast Cancer and to support other UNC Lineberger research initiatives.
FDA granted Fast Track designation to the phase III registration program for enobosarm, a selective androgen receptor targeting agonist, for the treatment of androgen receptor positive, estrogen receptor positive, human epidermal growth factor receptor 2 negative (AR+ER+HER2-) metastatic breast cancer patients who have shown previous disease progression on a nonsteroidal AI, Faslodex (fulvestrant), and CDK 4/6 inhibitor therapy, and who have AR% nuclei staining ≥40% in breast cancer tissue (third-line metastatic setting).
